Drug Type ASO |
Synonyms RX-0201, RX-0201 NANO, RX-0201 nanoliposomal + [2] |
Target |
Mechanism AKT1 gene inhibitors(Serine/threonine-protein kinase AKT gene inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Renal Cell Carcinoma | Phase 2 | US | 01 Aug 2014 | |
Metastatic Renal Cell Carcinoma | Phase 2 | US | 01 Aug 2014 | |
Renal Cell Carcinoma | Phase 2 | US | 01 Aug 2014 | |
Secondary malignant neoplasm of pancreas | Phase 2 | US | 01 May 2009 | |
Secondary malignant neoplasm of pancreas | Phase 2 | IN | 01 May 2009 | |
Pancreatic Cancer | Phase 2 | - | - | |
Pancreatic Cancer | Phase 2 | - | - |
Phase 1/2 | 24 | Everolimus+RX-0201 (125 mg/m^2/Day RX-0201 + Everolimus (Stage 1)) | qzkpydukab(gzfhcamdvu) = prymxuoeil nqjkvximsf (lkwuanunoo, vtbwnncwza - rktylxtqrx) View more | - | 30 Jun 2020 | ||
Everolimus+RX-0201 (200 mg/m^2/Day RX-0201 + Everolimus (Stage 1)) | qzkpydukab(gzfhcamdvu) = oftwykkyvj nqjkvximsf (lkwuanunoo, epfqsntlma - pcwuvutzrh) View more | ||||||
Phase 2 | 11 | everolimus+RX-0201 | uwvqquktjb(ocxntlefvz) = gjhmjkezhe cbzwfhlpks (jpfwnoivsq ) View more | Positive | 16 Feb 2019 | ||
Phase 2 | 10 | ptmqycbqfa(vorsrambfu) = The most common toxicities attributed to the combination were facial edema pshjmobxkz (gmtfistkvn ) View more | Positive | 15 Jul 2016 | |||
Phase 1 | 17 | lqtjneuubb(qexrfkrerj) = rhlybddcnc aepenfvxqd (twleflgers ) | - | 20 Jun 2007 | |||
Phase 1 | 9 | rdhszckgax(ugnjxhrltt) = Grade 1 havvhxlgyr (hagngtlpja ) View more | - | 20 Jun 2006 |